Idiopathic pulmonary fibrosis (IPF) is a condition that has a poor prognosis, with a median
survival of 4-5 years irrespective of treatment. Ziesche et al (N Engl J Med 1999, 341: 1264 …

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrosing interstitial
pneumonia of unknown aetiology and is associated with the histological picture of usual …

Idiopathic pulmonary fibrosis (IPF), the most common and severe interstitial lung disease,
remains a great challenge for clinicians. The natural history of the disease is incompletely …

The long-standing need to determine an effective medical treatment regimen with clinically
significant and relevant end-points to improve outcome for patients with idiopathic …

Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown aetiology with
deteriorating respiratory function leading to respiratory failure. Sequential acute lung injury …

PURPOSE: Idiopathic Pulmonary Fibrosis (IPF) is characterized by progressive respiratory
insufficiency and a median survival of only 2-5 years. There is no therapy for IPF with …

Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown etiology with an
unfavorable outcome from progressively deteriorating respiratory function, leading ultimately …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia characterized
by a poor response to therapy and a dismal prognosis. Historically, the fibrotic process in IPF …

Objective: To examine the clinical aspects of idiopathic pulmonary fibrosis (IPF) and the
efficacy and safety of interferon gamma-1b (IFNγ− 1b) in its treatment. Data Sources …

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive disease with inadequate
response to conventional treatment with corticosteroids and/or immunosuppressive agents …